However, Parp inhibitors currently employed in the clinic to treat cancer ‘trap’ the enzyme on DNA and cause additional cytotoxicity16, and therefore successful treatment of neurological disease will likely require the development of non-trapping Parp inhibitors capable of crossing the blood-brain barrier9. This evidence concerns the gene PARP1 and nervous system disorder.